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Abstract 
Background: The thieno[2,3-b]pyridines were discovered by virtual high throughput screening as potential inhibitors 
of phospholipase C (PLC) isoforms and showed potent growth inhibitory effects in National Cancer Institute’s human 
tumour cell line panel (NCI60). The mechanism of the anti-proliferative activity of thieno[2,3-b]pyridines is explored 
here.
Objectives: We aimed to investigate the basis for the anti-proliferative activity of these thieno[2,3-b]pyridines and to 
determine whether the cellular inhibition was related to their inhibition of PLC.
Methods: Four breast cancer cell lines were used to assess the anti-proliferative effects (IC50 values) of six repre-
sentative thieno[2,3-b]pyridines. The most potent compound (derivative 3; NSC768313), was further studied in 
MDA-MB-231 cells. DNA damage was examined by γH2AX expression level, and cell cycle arrest by flow cytometry. 
Cell morphology was examined by tubulin antibody staining. The growth inhibitory effect of combination treatment 
with derivative 3 and paclitaxel (tubulin inhibitor), doxorubicin (topoisomerase II inhibitor) or camptothecin (topoi-
somerase I inhibitor) was evaluated. A preliminary mouse toxicity assay was used to evaluate the pharmacological 
properties.
Results: Addition of the thieno[2,3-b]pyridine derivative 3 to the MDA-MB-231 cells induced G2/M growth inhibi-
tion, cell cycle arrest in G2-phase, membrane blebbing and the formation of multinucleated cells. It did not induce 
DNA damage, mitotic arrest or changes in calcium ion flux. Combination of derivative 3 with paclitaxel showed a high 
degree of synergy, while combinations with doxorubicin and camptothecin showed only additive effects. A mouse 
pharmacokinetic study of derivative 3 showed that after intraperitoneal injection of a single does (10 mg/Kg), the 
Cmax was 0.087 μmol/L and the half-life was 4.11 h.
Conclusions: The results are consistent with a mechanism in which thieno[2,3-b]pyridine derivatives interact with 
PLC isoforms (possibly PLC-δ), which in turn affect the cellular dynamics of tubulin-β, inducing cell cycle arrest in 
G2-phase. We conclude that these compounds have novelty because of their PLC target and may have utility in com-
bination with mitotic poisons for cancer treatment.
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Background
The phospholipase C (PLC) family comprises a series of 
enzymes [1] which regulate many cellular growth func-
tions, making them interesting targets for cancer therapy 
[2, 3]. The PLC isozymes are membrane bound proteins 
that hydrolyse phosphatidylinositol 4,5-diphosphate 
(PIP2) and generate two intracellular products: diacylg-
lycerol (DAG) and inositol 1,4,5-triphosphate (IP3) [4–6]. 
PLC is critical to cofilin regulation of actin polymerization 
which triggers the chemotaxis of breast carcinoma cells 
to epidermal growth factor [7]. There are six subfamilies 
of the mammalian pi-PLC super-family, which are classi-
fied as PLC-β, PLC-γ, PLC-δ, PLC-ε, PLC-ζ and PLC-η. In 
breast cancer, PLC-δ1 and PLC-δ3 expression levels were 
positively correlated with disease staging or tumor size 
[8]. Knockdown of PLC-δ induced cell rounding, surface 
blebbing and nuclear fragmentation, reduced cell pro-
liferation and migration in breast cancer cell line MDA-
MB-231 [8].
The thieno[2,3-b]pyridines were initially discovered 
as potential inhibitors of PLC isoforms by virtual high 
throughput screen (vHTS) against the available crys-
tal structure of the PLC-δ1 isoform [2]. In vitro testing 
revealed that the most potent analogues had growth 
inhibitory activity at low nanomolar concentrations 
against the National Cancer Institute’s NCI60 human 
tumour cell line panel [9–12]. They were also active 
against a series of breast cancer cell lines [13]. The struc-
tures of the six derivatives are shown in Fig. 1.
Triple-negative breast cancers lack functional oestro-
gen, progesterone and HER2 receptors, and new effec-
tive targeted therapies are required for this subset [14]. 
The sensitivity of two triple-negative breast cancer cell 
lines [13] to thieno[2,3-b]pyridines prompted our further 
investigation of this series, firstly to explore the activ-
ity of further thieno[2,3-b]pyridine analogues, secondly 
to characterise the cellular basis their anti-proliferative 
activity, and thirdly to determine whether adequate 
plasma concentrations of the most active compound are 
achieved after in vivo administration.
Methods
Cell culture
Culture conditions have been described in detail previ-
ously [15]; human breast cancer cell lines MCF-7, T47D, 
MDA-MB-468, MDA-MB-231, human epithelial car-
cinoma cell line A431 and human colon cancer cell line 
HCT116 were purchased from the American Type Cul-
ture Collection (ATCC). Cells were grown in α-MEM 
containing 5  % fetal calf serum, insulin/transferrin/sele-
nium supplement, added according to the manufacturer’s 
instructions (Roche), as well as penicillin/streptomycin 
(100 U/ml and 100 μg/ml, respectively).
Cell proliferation assay
As described in detail previously [16], cell proliferation 
was measured using a thymidine incorporation assay by 
seeding 3000 cells in each well using 96 well plates with 
varying concentrations of inhibitors for 3  days. Experi-
ments were performed in triplicate with a minimum 
of two experimental repeats. Briefly, 3H-thymidine 
(0.04 µCi) was added to each well and incubated for 5 h, 
after which the cells were gathered onto glass fibre filters 
using an automated TomTec harvester. Filters were incu-
bated with Betaplate Scint and thymidine incorporation 
determined with Trilux/Betaplate counter showing the 
percentage of cells incorporated with 3H-thymidine into 
the DNA helix.
Calcium flux assay
A431 cells were plated onto 96 wells until confluent. Cells 
were loaded with 5 µM Fluo-4 acetoxymethyl ester with 
0.003 % pluronic acid and 2.5 mM Probenecid (Molecular 
Probes) for 30 min at 37 °C, then washed with buffer and 
incubated for another 30  min. Epidermal growth factor 
(EGF) (400  ng/ml) was used as an activator. EGF alone 
or with derivative 3 were added to A431 cells to deter-
mine the inhibitory activity on calcium flux of derivative 
3, and compared with buffer (negative control) and 1 µg/
ml ionomycin (positive control). Fluorescence signal was 
recorded from the bottom of the plate at 1  s intervals 
Fig. 1 The structures of the thieno[2,3-b]pyridine derivatives 1–6
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(3 wells per/s) using an EnSpire 2300 Multimode Plate 
Reader (Perkin-Elmer) at excitation wavelength of 
494 nm and emission wavelength of 506 nm (25 °C, 3 mm 
measurement height, 50 flashes). Baseline fluorescence 
was recorded for 10  s, after which buffer alone, EGF 
alone or with drug, was added and fluorescence was cap-
tured for a further 45 s. Next, ionomycin was added and 
fluorescence was recorded for another 45 s. Three inde-
pendent experiments were performed.
Microtubule imaging
Cells were grown on a glass slide with and without inhibi-
tors, fixed by 4  % paraformaldehyde, permeabilised by 
0.5  % Triton X-PBS and incubated with 5  % BSA/PBS 
containing FITC-labelled anti-tubulin antibody. Micro-
tubule arrangement was monitored by fluorescence 
staining of microtubules using anti-tubulin and analysed 
by fluorescent microscopy using Floid imaging station 
(460×  magnification). Nucleus was stained with 2  μg/
ml Hoechst stain (Life Technology) for 10  min at room 
temperature. Hoechst stain emits blue fluorescence when 
bound to double strand DNA.
Flow cytometric analysis
As described in detail previously [17], cells (106 cells per 
well) were grown in 6 well plates and incubated with 
inhibitors for the indicated time. Cells were harvested, 
washed and resuspended in 1 ml of blocking buffer (1 % 
FCS/PBS), and incubated with antibody to γ-H2AX 
(phosphorylated Ser139) (Millipore, USA) in blocking 
buffer (1:500 dilution) at room temperature for 2 h. Cells 
were washed, incubated with goat anti-mouse Alex 488 
Fab fragment secondary antibody (Invitrogen, New Zea-
land) (1:400 in blocking buffer for 1 h, at room tempera-
ture; dark), washed and resuspended in 1 ml of blocking 
buffer containing RNase (1 μg/ml) and propidium iodide 
(PI) (10  μg/ml) for 30  min at room temperature. Cells 
were analysed in a Becton–Dickinson LSRII and profiles 
were analysed with ModFit LT 3 software.
Immunoblotting
As described in detail previously [15] cells were grown to 
log-phase, washed twice with ice-cold PBS, and lysed in 
SDS lysis buffer according to the manufacturer’s protocol 
(Cell Signalling Technology, Danvers, MA, USA). Pro-
tein concentration was quantified using the BCA protein 
assay reagent bicinchoninic acid (Sigma, New Zealand). 
Cell lysates containing 25 μg of protein were separated by 
SDS-PAGE and transferred to PVDF membranes (Milli-
pore). Membranes were immunoblotted with antibodies 
against to γ-H2AX (phosphorylated Ser139) (Millipore, 
USA), and actin (Millipore), using SuperSignalWest Pico 
(Thermo Scientific, Waltham,MA, USA) chemilumines-
cence reagents. Antibody reactivity was visualized using 
the chemiluminescence detection system by Fujifilm 
Las-3000.
Data analysis
As described previously for everolimus and other inhibi-
tors [15], we employed the Bliss additivism model [18] 
to classify the drug combinations as additive, syner-
gistic or antagonistic. A theoretical curve was cal-
culated for combined inhibition using the equation 
Ebliss =  (EA + EB) −  (EA × EB), where EA and EB are 
the fractional inhibitions obtained by drug A alone and 
drug B alone at specific concentrations. Ebliss is the frac-
tional inhibition that would be expected if the effects 
of the two drugs were additive. The difference (Bliss) in 
the experimentally measured fractional inhibition (Expt) 
and Ebliss are defined as synergism (Expt  <  Ebliss), addi-
tive (Expt = Ebliss), and antagonism (Expt > Ebliss). Bliss = 0 
would indicate the combination is additive; Bliss  >  0 
would indicate the percentage increase in maximal inhi-
bition above additivity (synergy); and Bliss  <  0 would 
indicate the percentage decrease in maximal inhibition 
below additivity (antagonism). The data were analysed 
using a one-way ANOVA coupled with multiple compar-
isons versus treatment control applying the Holm-Sidak 
method correction, where p < 0.05 denotes a statistically 
significant difference.
Mouse plasma pharmacokinetics
Male CD-1 mice were obtained from Vernon Jansen 
Unit (University of Auckland) and housed in cages with 
a 12-hour light/dark cycle and received sterilized food 
and water ad libitum. Studies and procedures were con-
ducted with prior approval of the Ethics Committee of 
the University of Auckland (AEC approval number 1190). 
Derivative 3 was prepared in 20 % HP-β CD as a fine yel-
low suspension, and administered (at 10 mg/Kg) as intra-
peritoneal bolus injection. Blood samples were collected 
via a terminal cardiac bleeding (n  =  3 mice/time) at 
0.167, 0.5, 1, 2 and 6 h post dose. Blood was collected in 
ice cold K2-EDTA tubes and kept on ice. All samples were 
centrifuged at 6500 rpm for 5 min at room temperature, 
obtained plasma were stored at −80 °C until analysed by 
LC–MS/MS.
Briefly, plasma samples were assayed for derivative 3 
using liquid chromatography-tandem mass spectrom-
etry (LC–MS/MS) method. Briefly, derivative 3 was 
spiked in the drug mouse plasma to obtain a concen-
tration 0.003, 0.03, 0.3, 3, 10 and 30 µM to construct a 
calibration curve. Derivative 1 (a structural analogue of 
3) was used as an internal standard in LC–MS/MS assay 
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at a concentration of 0.5 μM added to acetonitrile. Drug 
was extracted from plasma using direct protein precipi-
tation with ice cold acetonitrile (1:4 v/v) and quantified 
by peak area ratio of 3 versus 1 using a calibration curve 
prepared with derivative 3 as outlined above. LC–MS/
MS used was Agilent 6410b with multimode ion source 
operated in atmospheric pressure chemical ioniza-
tion (APCI) positive mode attached to an Agilent 1200 
series HPLC system. LC–MS/MS used an Agilent Zor-
bax SB-C18 column (2.1 × 50 mm, 5 µM, USA) operated 
at 35 °C, at a flow rate 0.5 mL/min with a gradient con-
sisting of 0.01 % formic acid in MilliQ water (Millipore, 
USA) and 0.01  % formic acid in 80  % acetonitrile-20  % 
MilliQ water. The MS1 and MS2 were operated at unit 
resolution in the multiple reaction monitoring (MRM) 
mode, monitoring the transition of the protonated 
molecular ions at m/z 368 to the product ions at m/z 245 
for derivative 3 and monitoring the transition of the pro-
tonated molecular ions at m/z 372 to the product ions at 
m/z 245 for derivative 1 (internal standard). No interfer-
ence of derivative 1 fragment (372  >  245) to derivative 
3 fragment (368  >  245) was observed in MRM chan-
nel. The lower limit of quantification for derivative 3 in 
plasma was 0.003 μM.
Mean mouse plasma-time data for derivative 3 was 
analysed with non-compartmental method using Phoe-
nix WinNonlin 6.2 (Pharsight Corporation, Mountain 
View, CA) as shown in Table 1.
Results
Thieno[2,3‑b]pyridine derivatives inhibit cell proliferation
The effect of derivatives 1–6 on the proliferation of four 
breast cancer cell lines (MCF7, T47D, MDA-MB-231 
and MDA-MB-468) was measured using a thymidine 
uptake assay [19], as shown in Fig.  2. The IC50 val-
ues were comparable (Spearman Rank Order Correla-
tion with r  =  0.708, p  <  0.0001) with those previously 
reported results from the NCI60 human tumour cell line 
panel on the same cell lines using the sulforhodamine B 
assay for cell density determination [10–12, 13]. Deriva-
tive 3 (NSC768313), with a methoxy substitution at the 
meta position, was the most active; IC50  <  100  nM for 
all the cell lines tested except for T47D and the triple-
negative MDA-MB-231, and was chosen for the further 
studies.
A COMPARE [20] analysis (based on the NCI60 data) 
of the growth inhibition patterns of different tumour cell 
lines by the thieno[2,3-b]pyridine derivative 3 showed 
Pearson correlation coefficient (PCC) of 0.512 with a 
mitotic kinesin Eg5 inhibitor S-trityl-l-cysteine [21], the 
G2-phase arresting agent cytembena [22] (PCC = 0.456), 
the microtubule poison vinblastine [23] (PCC =  0.456), 
and the microtubule poison paclitaxel [24] (PCC = 0.3).
Thieno[2,3‑b]pyridine derivative 3 induces G2/M cell cycle 
arrest but not DNA damage
The effect of the derivative 3 on the cell cycle distribution 
of MBA-MB-231 tumour cells was investigated by flow 
cytometry. DNA damage was measured by the increase 
of phosphorylated protein γH2AX, which is a well-estab-
lished biomarker for DNA double strand breakage [25]. 
The effects were compared with those of camptothecin as 
a typical DNA damaging agent. Derivative 3 did not initi-
ate DNA damage comparable to camptothecin (increased 
in the phosphorylated protein γH2AX from basal level of 
1 % to camptothecin treated 69 %) but did induce G2/M 
phase cell cycle arrest (Fig. 3a, b, c).
Thieno[2,3‑b]pyridine derivative 3 induces a 
multinucleated phenotype but not mitotic arrest
Earlier flow cytometry showed that the thieno[2,3-b]pyri-
dine derivative 1 caused G2/M arrest [13], which is also 
observed with tubulin poisons [26]. We next examined the 
Table 1 The results of the pharmacokinetic study
Ke elimination rate constant, t1/2 elimination half-life, Cmax maximum 
concentration in plasma, AUC area under the plasma concentration–time curve 
up to 6 h and extrapolated to infinity
Parameter Value
Ke,1/h 0.017
t1/2, h 4.11
Cmax, µmol/L 0.087
AUC0–6 h, µmol/L × h 0.13
AUC0–∞, µmol/L × h 0.19
0 
100 
200 
300 
400 
500 
600 
700 
800 
900 
1000 
1 2 3 4 5 6 
IC
50
 (n
M
) 
MCF7 
T47D 
MDA-MB-231 
MDA-MB-468 
Fig. 2 Thieno[2,3-b]pyridines derivatives inhibit cell proliferation. 
Relative thymidine incorporation of a panel of breast cancer cell lines 
was measured after 3 days treatment of derivatives 1–6. IC50 values 
(50 % inhibition of growth) are shown in nanomolar (nM). IC50 value 
was not reached for the concentration tested for derivative 5 in T47D 
cell line
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effects of derivative 3 on microtubule formation in MDA-
MB-231. Organised cytoplasmic microtubules complexes 
radiate from the centromere of the cells is shown in the 
control MDA-MB-231 cells. Derivative 3 treated cells 
exhibited abnormal nuclear phenotype and possessed 
multinuclear cells (Fig. 4). As expected, paclitaxel induced 
the shortened and bundling of microtubules. No microtu-
bule bundles were observed, suggesting derivative 3 had a 
different mechanism from that of paclitaxel. Derivative 3 
initiated the cells to round up as previously seen [13] but 
they also induced the formation of membrane protrusions 
on the cell surface (membrane blebbing).
Thieno[2,3‑b]pyridine derivative 3 has no effect on calcium 
flux
It is established that PLC-γ isoforms are involved in regu-
lating calcium ion flux while PLC-δ1 isoform is a calcium 
response element operating downstream of other PLC’s 
[8, 27]. To examine whether derivative 3 could reduce the 
Ca2+ mobilization in the cell cytosol, we examined the 
response of squamous carcinoma A431 cells by adding 
epidermal growth factor (EGF) following pre-treatment 
with derivative 3 at 25 and 50 μM (Fig. 5). The A431 cell 
line was chosen because it has been previously used to 
monitor calcium concentration for the thieno[2,3-b]pyr-
idines [2]. Derivative 3 had no effect on the increase in 
intracellular calcium levels induced by EGF.
Interactions between thieno[2,3‑b]pyridine derivative 3 
and cytotoxic drugs
The ability of the thieno[2,3-b]pyridine derivative 3 to 
modulate the effects of the cytotoxic drugs doxoru-
bicin, camptothecin or paclitaxel was explored in MDA-
MB-231 cells. The Bliss independence model [28] was 
a
b c
Fig. 3 Thieno[2,3-b]pyridine induces G2/M cell cycle arrest but not DNA damage. MDA-MB-231 breast cancer cells treated by derivative 3 (1 μM) 
or camptothecin (1 μM) for 24 h. a The effect of DNA damage was shown as relative measure of γH2AX abundance in the MDA-MB-231 breast 
cancer cells. Cellular immunofluorescence (anti-γ-H2AX antibody; y-axis) is plotted against DNA content (propidium iodide staining; x-axis). The top 
half (marked by dashed line) represents high γ-H2AX phosphorylation and the proportion of the total is indicated. b The cell cycle proportions of 
MDA-MB-231 treated by derivative 3 (1 μM) or camptothecin (1 μM) for 24 h. Population of G2/M phase was significantly increased by derivative 3. c 
Immunoblot for the phosphorylated γ-H2AX in the MDA-MB-231 breast cancer cell line. Actin was used as a loading control
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used to assess drug interactions. The topoisomerase I 
poison camptothecin and the topoisomerase II poison 
doxorubicin, which target topoisomerase I and II, respec-
tively, showed only additive effects with derivative 3 but 
for paclitaxel a synergistic effect is seen. Synergism with 
paclitaxel and derivative 3 was also observed in colon 
cancer cell line HCT116 (Fig. 6).
Thieno[2,3‑b]pyridine derivative 3 induces acceptable 
growth inhibitory plasma concentrations in mouse plasma
Derivative 3 was chosen for a small pharmacokinetic 
study. It showed poor aqueous solubility and was there-
fore formulated in 20  % hydroxypropyl β cyclodextrin 
(HP-β CD), resulting in a fine yellow suspension. This was 
administered at a dose of 10  mg/Kg by intraperitoneal 
injection and was well tolerated with no acute reaction 
observed. The plasma concentration is shown as a func-
tion of time in Fig. 7 and pharmacokinetic data are shown 
in Table 1. The maximal plasma concentration achieved 
in mice (30 min post injection) was 0.087 μmol/L and the 
half-life was over 4 h.
Discussion
Our results provide new information on mechanism 
of the thieno[2,3-b]pyridines and their potential for 
development in anticancer therapy. We have identified 
NSC768313 (derivative 3) as a potent derivative in this 
series and shown that it inhibits the proliferation of two 
triple negative human breast cancer cell lines, as well as 
one of two oestrogen receptor positive cell lines, at a con-
centration of  <100  nM. The derivative causes morpho-
logical changes including membrane blebbing, as well as 
inducing G2-phase arrest. The results appear to rule out 
DNA damage, mitotic arrest and increased calcium ion 
flux as mechanisms of growth inhibition.
Three results suggest that the thieno[2,3-b]pyridines 
act on events leading to mitosis. Firstly, results from flow 
cytometry and fluorescence microscopy indicate arrest 
in the G2-phase rather than metaphase. Secondly, COM-
PARE analysis suggests that the growth inhibitory effects 
are related in some way to those of the mitotic poisons 
vinblastine and paclitaxel. However, they are also related 
to those of S-trityl-l-cysteine and cytembena, which 
induce G2-phase arrest but not mitotic arrest. Thirdly, 
derivative 3 shows strong synergy with paclitaxel but 
not with doxorubicin and camptothecin in their growth 
arrest of MDA-MB-231 cells.
The cellular effects of the thieno[2,3-b]pyridine 
derivative 3 are comparable to those observed in 
MDA-MB-231 breast cancer cells following PLC–δ1 
and –δ3 gene knockdown [8], which induces severe 
growth inhibition and G2-phase cell cycle arrest. The 
effects are also similar to those of the thieno[2,3-b]
pyridine derivative 1 [8, 13]. Phosphatidylinositol 
Fig. 4 Thieno[2,3-b] induce multinucleated phenotype but not 
microtubules bundle formation. The effect of paclitaxel and derivative 
3 on MDA-MB-231 breast cancer cells with microtubule filaments 
stained with FITC-labelled anti-tubulin antibody (green fluores-
cence). DNA in the nucleus was stained with Hoechst staining (blue 
fluorescence). Cells were treated with or without drugs for 16 h. Multi-
nucleated cells were observed by derivative 3 treatment. The arrow 
indicates membrane blebbing
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4,5-bisphosphate (PIP2) coordinates actin polymeri-
sation and the formation of the filopodia membrane 
for cell adhesion [29]. Since PLC–δ1 binds directly 
to PIP2, the change of cell morphology (cell round-
ing and membrane blebbing) supports the hypothesis 
that thieno[2,3-b]pyridines act as PLC–δ1 inhibitors. 
It is of interest that PLC1, the yeast homologue 
of PLC-δ1, localizes at the centromeric loci at the 
G2/M checkpoint and is essential for cell growth [8]. 
There is evidence that PLC–γ interacts directly with 
β-tubulin through pleckstrin homology domains 
[30], which are also present in PLC–δ1 [31]. We were 
unfortunately not able to test the effects of this series 
of thieno[2,3-b]pyridines on PLC–δ1 in a cell-free 
assay. The compounds were tested for PLC-β/γ inhi-
bition; no effect was found for PLC-β and the order 
of potency for the inhibition of PLCγ was different 
from that for inhibition of cell proliferation (data not 
shown). We suggest that active thieno[2,3-b]pyridine 
derivatives interact with PLC isozymes, which then 
inhibit the function of the cytoskeleton. Changes to 
tubulin lead to aberrant mitoses and to subsequent 
multinucleate cells and synergy with paclitaxel. 
Changes to actin may also contribute to the observed 
morphological changes.
Preliminary experiments show that derivative 3 has 
acceptable pharmacological properties. Although a pre-
liminary mouse xenograft study showed reduction of 
tumour size and mass upon intraperitoneal dosing with 
thieno[2,3-b]pyridine derivative 4 (Fig.  1), the results 
did not reach statistical significance [32]. Future work 
will focus on finding new analogues in this series with 
increased aqueous solubility as well as expanding struc-
ture–activity relationships (SAR) for the series. More 
effective analogues, in conjunction with molecular mod-
elling studies, could then be used to evaluate in  vivo 
Fig. 5 Thieno[2,3-b]pyridine has no effect on calcium flux. Calcium flux measured in A431 cells with and without pre-treatment of derivative 3. EGF 
(400 ng/ml) was added at the time marked by the first vertical arrow, followed by ionomycin (1 µg/ml) as indicated, as a positive control
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antitumour activity as well as identifying the biochemical 
target of action.
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CPT camptothecin, DOX doxorubicin, TAXOL paclitaxel; and PLC, derivative 3. The dashed line represents the theoretical expectation when the com-
bined effects of chemicals are additive (Bliss curve)
Time (h)
0 2 4 6 8
P
la
sm
a 
co
nc
en
tra
tio
n 
(
m
ol
/L
)
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Fig. 7 Plasma concentrations in CD1 male mice as a function of 
time after administration of derivative 3. Mice, (n = 3); derivative 3, 
(10 mg/Kg)
Page 9 of 9Reynisson et al. Cancer Cell Int  (2016) 16:18 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Competing interests
The authors declare that they have no competing interests.
Received: 19 November 2015   Accepted: 1 March 2016
References
 1. Kadamur G, Ross EM. Mammalian phospholipase C. Ann Rev Physiol. 
2013;75:127–54. doi:10.1146/annurev-physiol-030212-183750.
 2. Reynisson J, Court W, O’Neill C, Day J, Patterson L, McDonald E, et al. 
The identification of novel PLC-c inhibitors using virtual high through-
put screening. Bioorg Med Chem. 2009;17:3169–76. doi:10.1016/j.
bmc.2009.02.049.
 3. Kölsch V, Charest PG, Firtel RA. The regulation of cell motility and chemo-
taxis by phospholipid signaling. J Cell Sci. 2008;121:551–9. doi:10.1242/
jcs.023333.
 4. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu 
Rev Biochem. 2001;70:281–312. doi:10.1146/Annurev.Biochem.70.1.281.
 5. Wells A, Grandis JR. Phospholipase C-gamma1 in tumor progression. Clin 
Exp Metastasis. 2003;20(4):285–90.
 6. Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoi-
nositide-specific phospholipase C. Physiol Rev. 2000;80(4):1291–335.
 7. van Rheenen J, Condeelis J, Glogauer M. A common cofilin activity cycle 
in invasive tumor cells and inflammatory cells. J Cell Sci. 2009;122(Pt 
3):305–11. doi:10.1242/jcs.031146.
 8. Rebecchi MJ, Raghubir A, Scarlata S, Hartenstine MJ, Brown T, Stallings 
JD. Expression and function of phospholipase C in breast carcinoma. Adv 
Enzyme Regul. 2009;49(1):59–73. doi:10.1016/j.advenzreg.2009.01.009.
 9. Shoemaker RH. The NCI60 Human Tumour Cell line Anticancer Drug 
Screen. Nat Rev Drug Dis. 2006;6:813–23. doi:10.1038/nrc1951.
 10. Feng L, Reynisdóttir I, Reynisson J. The effect of PLC-gamma2 inhibitors 
on the growth of human tumour cells. Eur J Med Chem. 2012;54:463–9. 
doi:10.1016/j.ejmech.2012.05.029.
 11. Arabshahi HJ, Leung E, Barker D, Reynisson J. The development of 
thieno[2,3-b]pyridine analogues as anticancer agents applying in silico 
methods. Med Chem Comm. 2014;5:186–91. doi:10.1039/c3md00320e.
 12. Hung JM, Arabshahi HJ, Leung E, Reynisson J, Barker D. Synthesis and 
cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives. 
Eur J Med Chem. 2014;86:420–37. doi:10.1016/j.ejmech.2014.09.001.
 13. Leung E, Hung JM, Barker D, Reynisson J. The effect of a thieno[2,3-b] pyri-
dine PLC-gamma inhibitor on the proliferation, morphology, migration 
and cell cycle of breast cancer cells. Medchemcomm. 2014;5(1):99–106. 
doi:10.1039/C3md00290j.
 14. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet 
medical need. Oncologist. 2011;16(Suppl 1):1–11. doi:10.1634/
theoncologist.2011-S1-01.
 15. Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC. Poten-
tiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus 
by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. PLoS 
ONE. 2015;10(7):e0131400. doi:10.1371/journal.pone.0131400.
 16. Leung EY, Kim JE, Askarian-Amiri M, Rewcastle GW, Finlay GJ, Baguley 
BC. Relationships between signaling pathway usage and sensitivity to 
a pathway inhibitor: examination of trametinib responses in cultured 
breast cancer lines. PLoS ONE. 2014;9(8):e105792. doi:10.1371/journal.
pone.0105792.
 17. Leung E, Rewcastle GW, Joseph WR, Rosengren RJ, Larsen L, Baguley BC. 
Identification of cyclohexanone derivatives that act as catalytic inhibitors 
of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. 
Invest New Drugs. 2012;30(6):2103–12. doi:10.1007/s10637-011-9768-4.
 18. Berenbaum MC. Criteria for analyzing interactions between biologi-
cally active agents. Adv Cancer Res. 1981;35:269–335. doi:10.1016/
S0065-230X(08)60912-4.
 19. Goncharova EA, Lim P, Goncharov DA, Eszterhas A, Panettieri RA, Krym-
skaya VP. Assays for in vitro monitoring of proliferation of human airway 
smooth muscle (ASM) and human pulmonary arterial vascular smooth 
muscle (VSM) cells. Nat Protocols. 2007;1(6):2905–8.
 20. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein 
LA, et al. Display and analysis of patterns of differential activity of drugs 
against human tumor cell lines: development of mean graph and COM-
PARE algorithm. J Natl Cancer Inst. 1989;81(14):1088–92.
 21. DeBonis S, Skoufias DA, Indorato R-L, Liger F, Marquet B, Laggner C, et al. 
Structure-activity relationship of S-Trityl-l-Cysteine analogues as inhibi-
tors of the human mitotic kinesin Eg5. J Med Chem. 2008;51(5):1115–25. 
doi:10.1021/jm070606z.
 22. Ronot X, Adolphe M, Kuch D, Jaffray P, Lechat P, Deysson G. Effect of 
sodium cis-beta-4-methoxybenzoyl-beta-bromacrylate (Cytembena) on 
HeLa cell kinetics. Cancer Res. 1982;42(8):3193–5.
 23. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin 
and nocodazole on mitotic spindles. Implications for the role of microtu-
bule dynamics in mitosis. J Cell Sci. 1992;102(Pt 3):401–16.
 24. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat 
Rev Cancer. 2004;4(4):253–65. doi:10.1038/nrc1317.
 25. Kobayashi J, Tauchi H, Sakamoto S, Nakamura A, Ken-ichi Morishima K, 
Matsuura S, et al. NBS1 Localizes to γ-H2AX Foci through interaction 
with the FHA/BRCT domain. Curr Biol. 2002;12(21):1846–51. doi:10.1016/
S0960-9822(02)01259-9.
 26. Michieli P, Di Nicolantonio F. Tivantinib—a cytotoxic drug in MET 
inhibitor’s clothes? Nat Rev Clin Oncol. 2013;10:372–4. doi:10.1038/
nrclinonc.2013.86.
 27. Vines CM, Phospholipase C. Adv Exp Med Biol. 2012;740:235–54. 
doi:10.1007/978-94-007-2888-2_10.
 28. Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 
1939;26(3):585–615. doi:10.1111/j.1744-7348.1939.tb06990.x.
 29. Chierico L, Joseph AS, Lewis AL, Battaglia G. Live cell imaging of mem-
brane/cytoskeleton interactions and membrane topology. Scientific Rep. 
2014;4:6056. doi:10.1038/srep06056.
 30. Chang JS, Kim SK, Kwon TK, Bae SS, Min DS, Lee YH, et al. Pleckstrin 
homology domains of phospholipase C-gamma1 directly interact with 
beta-tubulin for activation of phospholipase C-gamma1 and reciprocal 
modulation of beta-tubulin function in microtubule assembly. J Biol 
Chem. 2005;280(8):6897–905. doi:10.1074/jbc.M406350200.
 31. Garcia P, Gupta R, Shah S, Morris AJ, Rudge SA, Scarlata S, et al. The 
pleckstrin homology domain of phospholipase C-delta 1 binds with high 
affinity to phosphatidylinositol 4,5-bisphosphate in bilayer membranes. 
Biochemistry. 1995;34(49):16228–34.
 32. Arabshahi HJ, van Rensburg M, Pilkington LI, Jeon CY, Song M, Gridel 
L-M, et al. A synthesis, in silico, in vitro and in vivo study of thieno[2,3-b]
pyridine anticancer analogues. Medchemcomm. 2015;6(11):1987–97. 
doi:10.1039/C5MD00245A.
